The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of bevacizumab and fotemustine in recurrent grade III gliomas.
Riccardo Soffietti
No relevant relationships to disclose
Elisa Trevisan
No relevant relationships to disclose
Chiara Bosa
No relevant relationships to disclose
Luca Bertero
No relevant relationships to disclose
Roberta Ruda
No relevant relationships to disclose